{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:01:01Z","timestamp":1790308861323,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Small cell lung cancer (SCLC) is an aggressive malignancy that responds poorly to immune checkpoint inhibitor (ICI) therapy, due to its immunosuppressive tumor microenvironment. Here, we analyse preclinical mouse tumor models and patient-derived SCLC samples and identify Exportin 1 (XPO1) as a regulator of immune suppression in SCLC. Mechanistically, XPO1 drives the nuclear export of TRIM21, enabling TRIM21-dependent proteasomal degradation of IRF3 and repressing the immunostimulatory cytokine TNFSF15. Loss of TNFSF15 promotes TREM2\n                    <jats:sup>+<\/jats:sup>\n                    macrophage polarization, which subsequently attenuates macrophage-dependent IFN-\u03b3-STAT1 signaling and MHC class I expression in tumor cells. Pharmacological or genetic XPO1 blockade restores TNFSF15, constrains TREM2\n                    <jats:sup>+<\/jats:sup>\n                    macrophage differentiation, reactivates antigen presentation, and enhances anti-PD-1 efficacy in preclinical mouse models. Thus, our findings link XPO1-dependent nuclear export to TREM2+ macrophage polarization and support evaluation of XPO1 inhibition in combination with ICIs in SCLC.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-76862-0","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T07:29:03Z","timestamp":1787383743000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["XPO1-mediated TRIM21 nuclear export reprograms TREM2+ macrophage polarization by targeting IRF3 to augment anti-PD-1 efficacy in small cell lung cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Qingwu","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yantao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingzhi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"76862_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"76862_CR2","first-page":"620","volume":"73","author":"Z Megyesfalvi","year":"2023","unstructured":"Megyesfalvi, Z. et al. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J. Clin. 73, 620\u2013652 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"76862_CR3","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn, L. et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N. Engl. J. Med. 379, 2220\u20132229 (2018).","journal-title":"N. Engl. J. Med."},{"key":"76862_CR4","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares, L. et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394, 1929\u20131939 (2019).","journal-title":"Lancet"},{"key":"76862_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","volume":"19","author":"CM Rudin","year":"2019","unstructured":"Rudin, C. M. et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat. Rev. Cancer 19, 289\u2013297 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"76862_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","volume":"39","author":"CM Gay","year":"2021","unstructured":"Gay, C. M. et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 39, 346\u2013360 e347 (2021).","journal-title":"Cancer Cell"},{"key":"76862_CR7","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cell.2023.12.004","volume":"187","author":"Q Liu","year":"2024","unstructured":"Liu, Q. et al. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. Cell 187, 184\u2013203 e128 (2024).","journal-title":"Cell"},{"key":"76862_CR8","doi-asserted-by":"publisher","first-page":"e35770","DOI":"10.1002\/cncr.35770","volume":"131","author":"MD Shields","year":"2025","unstructured":"Shields, M. D., Chiang, A. C. & Byers, L. A. Top advances of the year: small cell lung cancer. Cancer 131, e35770 (2025).","journal-title":"Cancer"},{"key":"76862_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1101\/gad.349359.122","volume":"36","author":"KD Sutherland","year":"2022","unstructured":"Sutherland, K. D., Ireland, A. S. & Oliver, T. G. Killing SCLC: insights into how to target a shapeshifting tumor. Genes Dev. 36, 241\u2013258 (2022).","journal-title":"Genes Dev."},{"key":"76862_CR10","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jtho.2023.05.008","volume":"18","author":"CM Rudin","year":"2023","unstructured":"Rudin, C. M. et al. Clinical benefit from immunotherapy in patients with SCLC is associated with tumor capacity for antigen presentation. J. Thorac. Oncol. 18, 1222\u20131232 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"76862_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ccell.2025.01.012","volume":"43","author":"H Chen","year":"2025","unstructured":"Chen, H. et al. Integrative spatial analysis reveals tumor heterogeneity and immune colony niche related to clinical outcomes in small cell lung cancer. Cancer Cell 43, 519\u2013536 e515 (2025).","journal-title":"Cancer Cell"},{"key":"76862_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen, S. et al. Macrophages in immunoregulation and therapeutics. Signal Transduct. Target Ther. 8, 207 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"76862_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-017-0430-2","volume":"10","author":"L Yang","year":"2017","unstructured":"Yang, L. & Zhang, Y. Tumor-associated macrophages: from basic research to clinical application. J. Hematol. Oncol. 10, 58 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"76862_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49885-8","volume":"15","author":"A Coulton","year":"2024","unstructured":"Coulton, A. et al. Using a pan-cancer atlas to investigate tumour associated macrophages as regulators of immunotherapy response. Nat. Commun. 15, 5665 (2024).","journal-title":"Nat. Commun."},{"key":"76862_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202413445","volume":"12","author":"T Qin","year":"2025","unstructured":"Qin, T. et al. Nuclear to cytoplasmic transport is a druggable dependency in HDAC7-driven small cell lung cancer. Adv. Sci. 12, e2413445 (2025).","journal-title":"Adv. Sci."},{"key":"76862_CR16","first-page":"543","volume":"22","author":"T Qin","year":"2025","unstructured":"Qin, T., Wang, J. & Huang, D. XPO1 as a key regulator in small cell lung cancer: mechanisms, biomarkers, and therapeutic implications. Cancer Biol. Med. 22, 543\u2013548 (2025).","journal-title":"Cancer Biol. Med."},{"key":"76862_CR17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.canlet.2021.01.008","volume":"503","author":"J Wang","year":"2021","unstructured":"Wang, J. et al. XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a. Cancer Lett. 503, 197\u2013212 (2021).","journal-title":"Cancer Lett."},{"key":"76862_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf7006","volume":"15","author":"A Quintanal-Villalonga","year":"2023","unstructured":"Quintanal-Villalonga, A. et al. Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers. Sci. Transl. Med. 15, eadf7006 (2023).","journal-title":"Sci. Transl. Med."},{"key":"76862_CR19","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1158\/0008-5472.CAN-21-2964","volume":"82","author":"A Quintanal-Villalonga","year":"2022","unstructured":"Quintanal-Villalonga, A. et al. Inhibition of XPO1 sensitizes small cell lung cancer to first- and second-line chemotherapy. Cancer Res. 82, 472\u2013483 (2022).","journal-title":"Cancer Res."},{"key":"76862_CR20","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","volume":"15","author":"MK Baine","year":"2020","unstructured":"Baine, M. K. et al. SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization. J. Thorac. Oncol. 15, 1823\u20131835 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"76862_CR21","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","volume":"39","author":"CM Gay","year":"2021","unstructured":"Gay, C. M. et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 39, 346\u2013360.e7 (2021).","journal-title":"Cancer Cell"},{"key":"76862_CR22","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s42003-021-01842-7","volume":"4","author":"L Cai","year":"2021","unstructured":"Cai, L. et al. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer. Commun. Biol. 4, 314 (2021).","journal-title":"Commun. Biol."},{"key":"76862_CR23","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41467-025-67078-9","volume":"17","author":"Y Seo","year":"2026","unstructured":"Seo, Y. et al. Actin dysregulation induces neuroendocrine plasticity and immune evasion: a vulnerability of small cell lung cancer. Nat. Commun. 17, 386 (2026).","journal-title":"Nat. Commun."},{"key":"76862_CR24","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s13046-025-03542-0","volume":"44","author":"Y Fang","year":"2025","unstructured":"Fang, Y. et al. TEAD3 + high-risk melanoma cells crosstalk with GAS6 + macrophages via the GAS6-TYRO3 ligand-receptor axis to modulate propionate metabolism and drive melanoma progression. J. Exp. Clin. Cancer Res. 44, 279 (2025).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"76862_CR25","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.trecan.2022.12.002","volume":"9","author":"Y Wang","year":"2023","unstructured":"Wang, Y., Qiu, F. & Yan, J. Transcription factor c-Maf-targeted cancer immunotherapy. Trends Cancer 9, 265\u2013269 (2023).","journal-title":"Trends Cancer"},{"key":"76862_CR26","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.cell.2020.07.013","volume":"182","author":"M Molgora","year":"2020","unstructured":"Molgora, M. et al. TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy. Cell 182, 886\u2013900 e817 (2020).","journal-title":"Cell"},{"key":"76862_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adi5374","volume":"9","author":"B Di Luccia","year":"2024","unstructured":"Di Luccia, B. et al. TREM2 deficiency reprograms intestinal macrophages and microbiota to enhance anti-PD-1 tumor immunotherapy. Sci. Immunol. 9, eadi5374 (2024).","journal-title":"Sci. Immunol."},{"key":"76862_CR28","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2032918","volume":"11","author":"CC Zhao","year":"2022","unstructured":"Zhao, C. C. et al. TNFSF15 facilitates differentiation and polarization of macrophages toward M1 phenotype to inhibit tumor growth. Oncoimmunology 11, 2032918 (2022).","journal-title":"Oncoimmunology"},{"key":"76862_CR29","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41401-025-01663-y","volume":"47","author":"YP Zhu","year":"2026","unstructured":"Zhu, Y. P. et al. TNFSF15 alleviates myeloid-derived suppressor cell-mediated cancer immunosuppression in mice. Acta Pharm. Sin. 47, 493\u2013503 (2026).","journal-title":"Acta Pharm. Sin."},{"key":"76862_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217432","volume":"611","author":"S Kong","year":"2024","unstructured":"Kong, S. et al. Mechanisms of low MHC I expression and strategies for targeting MHC I with small molecules in cancer immunotherapy. Cancer Lett. 611, 217432 (2024).","journal-title":"Cancer Lett."},{"key":"76862_CR31","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","volume":"16","author":"F Blackhall","year":"2021","unstructured":"Blackhall, F. et al. Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study. J. Thorac. Oncol. 16, 1547\u20131558 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"76862_CR32","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","volume":"405","author":"L Paz-Ares","year":"2025","unstructured":"Paz-Ares, L. et al. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. Lancet 405, 2129\u20132143 (2025).","journal-title":"Lancet"},{"key":"76862_CR33","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1038\/s41591-024-03132-1","volume":"30","author":"Y Cheng","year":"2024","unstructured":"Cheng, Y. et al. Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial. Nat. Med. 30, 2967\u20132976 (2024).","journal-title":"Nat. Med."},{"key":"76862_CR34","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1159\/000534427","volume":"114","author":"Y Zou","year":"2024","unstructured":"Zou, Y. et al. Correlation of neuroendocrine differentiation with a distinctively suppressive immune microenvironment in gastric cancer. Neuroendocrinology 114, 192\u2013206 (2024).","journal-title":"Neuroendocrinology"},{"key":"76862_CR35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s11864-024-01283-4","volume":"26","author":"A Urman","year":"2025","unstructured":"Urman, A., Schonman, I. & De Jesus-Acosta, A. Evolving immunotherapy strategies in gastrointestinal neuroendocrine neoplasms. Curr. Treat. Options Oncol. 26, 92\u2013102 (2025).","journal-title":"Curr. Treat. Options Oncol."},{"key":"76862_CR36","doi-asserted-by":"crossref","unstructured":"Lyu, X. et al. Targeting TNFRSF25 by agonistic antibodies and multimeric TL1A proteins co-stimulated CD8(+) T cells and inhibited tumor growth. J. Immunother. Cancer 12, e008810 (2024).","DOI":"10.1136\/jitc-2024-008810"},{"key":"76862_CR37","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jconrel.2024.12.035","volume":"378","author":"X Ling","year":"2025","unstructured":"Ling, X. et al. Functionalized aluminum hydroxide-based self-adjuvanted nanovaccine orchestrates antitumor immune responses via Dectin-1 signaling. J. Control Rel. 378, 559\u2013572 (2025).","journal-title":"J. Control Rel."},{"key":"76862_CR38","doi-asserted-by":"crossref","unstructured":"Chelvanambi, M., Fecek, R. J., Taylor, J. L. & Storkus, W. J. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. J. Immunother. Cancer 9, e001906 (2021).","DOI":"10.1136\/jitc-2020-001906"},{"key":"76862_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105443","volume":"165","author":"M Alomari","year":"2021","unstructured":"Alomari, M. TRIM21 - a potential novel therapeutic target in cancer. Pharm. Res. 165, 105443 (2021).","journal-title":"Pharm. Res."},{"key":"76862_CR40","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.chembiol.2023.05.009","volume":"30","author":"YX Liu","year":"2023","unstructured":"Liu, Y. X. et al. TRIM21 is a druggable target for the treatment of metastatic colorectal cancer through ubiquitination and activation of MST2. Cell Chem. Biol. 30, 709\u2013725 e706 (2023).","journal-title":"Cell Chem. Biol."},{"key":"76862_CR41","doi-asserted-by":"crossref","unstructured":"Xia, L. et al. TRIM21-driven K63-linked ubiquitination of RBM38c, as a novel interactor of BECN1, contributes to DNA damage-induced autophagy. Cell Death Differ. 32, 1317\u20131335 (2025).","DOI":"10.1038\/s41418-025-01480-0"},{"key":"76862_CR42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2406936121","volume":"121","author":"WL Ye","year":"2024","unstructured":"Ye, W. L. et al. TRIM21 induces selective autophagic degradation of c-Myc and sensitizes regorafenib therapy in colorectal cancer. Proc. Natl. Acad. Sci. USA 121, e2406936121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76862_CR43","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.immuni.2025.03.008","volume":"58","author":"Y Shen","year":"2025","unstructured":"Shen, Y. et al. Alcaligenes faecalis induces intestinal T helper-17 cells by enhancing Rorc transcription through E3 ligase Trim21-mediated Fbxw7 degradation. Immunity 58, 1469\u20131483 e1468 (2025).","journal-title":"Immunity"},{"key":"76862_CR44","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.ymthe.2025.01.047","volume":"33","author":"J Shi","year":"2025","unstructured":"Shi, J. et al. Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy. Mol. Ther. 33, 1073\u20131090 (2025).","journal-title":"Mol. Ther."},{"key":"76862_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.818969","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. African swine fever virus MGF360-14L negatively regulates type I interferon signaling by targeting IRF3. Front. Cell Infect. Microbiol. 11, 818969 (2021).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"76862_CR46","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.4049\/jimmunol.181.3.1780","volume":"181","author":"R Higgs","year":"2008","unstructured":"Higgs, R. et al. The E3 ubiquitin ligase Ro52 negatively regulates IFN-beta production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3. J. Immunol. 181, 1780\u20131786 (2008).","journal-title":"J. Immunol."},{"key":"76862_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-11-24","volume":"11","author":"GD Manocha","year":"2014","unstructured":"Manocha, G. D. et al. Regulatory role of TRIM21 in the type-I interferon pathway in Japanese encephalitis virus-infected human microglial cells. J. Neuroinflamm. 11, 24 (2014).","journal-title":"J. Neuroinflamm."},{"key":"76862_CR48","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1083\/jcb.201503023","volume":"210","author":"T Kimura","year":"2015","unstructured":"Kimura, T. et al. TRIM-mediated precision autophagy targets cytoplasmic regulators of innate immunity. J. Cell Biol. 210, 973\u2013989 (2015).","journal-title":"J. Cell Biol."},{"key":"76862_CR49","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.3389\/fimmu.2018.02479","volume":"9","author":"H Liu","year":"2018","unstructured":"Liu, H., Li, M., Song, Y. & Xu, W. TRIM21 restricts coxsackievirus B3 replication, cardiac and pancreatic injury via interacting with MAVS and positively regulating IRF3-mediated type-I interferon production. Front. Immunol. 9, 2479 (2018).","journal-title":"Front. Immunol."},{"key":"76862_CR50","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.4049\/jimmunol.0803126","volume":"182","author":"K Yang","year":"2009","unstructured":"Yang, K. et al. TRIM21 is essential to sustain IFN regulatory factor 3 activation during antiviral response. J. Immunol. 182, 3782\u20133792 (2009).","journal-title":"J. Immunol."},{"key":"76862_CR51","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/ni.2548","volume":"14","author":"WA McEwan","year":"2013","unstructured":"McEwan, W. A. et al. Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat. Immunol. 14, 327\u2013336 (2013).","journal-title":"Nat. Immunol."},{"key":"76862_CR52","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1093\/emboj\/20.9.2140","volume":"20","author":"A Reymond","year":"2001","unstructured":"Reymond, A. et al. The tripartite motif family identifies cell compartments. EMBO J. 20, 2140\u20132151 (2001).","journal-title":"EMBO J."},{"key":"76862_CR53","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s10875-007-9157-0","volume":"28","author":"L Strandberg","year":"2008","unstructured":"Strandberg, L. et al. Interferon-alpha induces up-regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies. J. Clin. Immunol. 28, 220\u2013231 (2008).","journal-title":"J. Clin. Immunol."},{"key":"76862_CR54","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaut.2012.01.014","volume":"39","author":"V Oke","year":"2012","unstructured":"Oke, V. & Wahren-Herlenius, M. The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review. J. Autoimmun. 39, 77\u201382 (2012).","journal-title":"J. Autoimmun."},{"key":"76862_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32284-2","volume":"13","author":"SH Jung","year":"2022","unstructured":"Jung, S. H. et al. Spatiotemporal dynamics of macrophage heterogeneity and a potential function of Trem2(hi) macrophages in infarcted hearts. Nat. Commun. 13, 4580 (2022).","journal-title":"Nat. Commun."},{"key":"76862_CR56","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adk1866","volume":"16","author":"L Zhou","year":"2024","unstructured":"Zhou, L. et al. Hepatic danger signaling triggers TREM2(+) macrophage induction and drives steatohepatitis via MS4A7-dependent inflammasome activation. Sci. Transl. Med. 16, eadk1866 (2024).","journal-title":"Sci. Transl. Med."},{"key":"76862_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57024-0","volume":"16","author":"H Cui","year":"2025","unstructured":"Cui, H. et al. TREM2 promotes lung fibrosis via controlling alveolar macrophage survival and pro-fibrotic activity. Nat. Commun. 16, 1761 (2025).","journal-title":"Nat. Commun."},{"key":"76862_CR58","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/s41591-020-0939-8","volume":"26","author":"S Alivernini","year":"2020","unstructured":"Alivernini, S. et al. Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. Nat. Med. 26, 1295\u20131306 (2020).","journal-title":"Nat. Med."},{"key":"76862_CR59","doi-asserted-by":"publisher","first-page":"5284","DOI":"10.1158\/0008-5472.CAN-21-0101","volume":"81","author":"DN Huggins","year":"2021","unstructured":"Huggins, D. N. et al. Characterizing macrophage diversity in metastasis-bearing lungs reveals a lipid-associated macrophage subset. Cancer Res. 81, 5284\u20135295 (2021).","journal-title":"Cancer Res."},{"key":"76862_CR60","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/s41423-024-01199-x","volume":"21","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Lipid droplet accumulation mediates macrophage survival and Treg recruitment via the CCL20\/CCR6 axis in human hepatocellular carcinoma. Cell Mol. Immunol. 21, 1120\u20131130 (2024).","journal-title":"Cell Mol. Immunol."},{"key":"76862_CR61","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.immuni.2024.11.026","volume":"58","author":"J Waibl Polania","year":"2025","unstructured":"Waibl Polania, J. et al. Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion. Immunity 58, 232\u2013246 e236 (2025).","journal-title":"Immunity"},{"key":"76862_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114875","volume":"43","author":"S Keshari","year":"2024","unstructured":"Keshari, S. et al. Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy. Cell Rep. 43, 114875 (2024).","journal-title":"Cell Rep."},{"key":"76862_CR63","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","volume":"36","author":"ML Burr","year":"2019","unstructured":"Burr, M. L. et al. An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer. Cancer Cell 36, 385\u2013401 e388 (2019).","journal-title":"Cancer Cell"},{"key":"76862_CR64","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.ccr.2011.04.019","volume":"19","author":"KD Sutherland","year":"2011","unstructured":"Sutherland, K. D. et al. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 19, 754\u2013764 (2011).","journal-title":"Cancer Cell"},{"key":"76862_CR65","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1535-6108(03)00220-4","volume":"4","author":"R Meuwissen","year":"2003","unstructured":"Meuwissen, R. et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 4, 181\u2013189 (2003).","journal-title":"Cancer Cell"},{"key":"76862_CR66","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ccell.2020.05.001","volume":"38","author":"AS Ireland","year":"2020","unstructured":"Ireland, A. S. et al. MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate. Cancer Cell 38, 60\u201378 e12 (2020).","journal-title":"Cancer Cell"},{"key":"76862_CR67","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cell.2018.05.060","volume":"174","author":"E Azizi","year":"2018","unstructured":"Azizi, E. et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 174, 1293\u20131308 e1236 (2018).","journal-title":"Cell"},{"key":"76862_CR68","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","volume":"524","author":"J George","year":"2015","unstructured":"George, J. et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524, 47\u201353 (2015).","journal-title":"Nature"},{"key":"76862_CR69","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1158\/1541-7786.MCR-12-0139","volume":"10","author":"S Kastner","year":"2012","unstructured":"Kastner, S. et al. Expression of G protein-coupled receptor 19 in human lung cancer cells is triggered by entry into S-phase and supports G(2)-M cell-cycle progression. Mol. Cancer Res. 10, 1343\u20131358 (2012).","journal-title":"Mol. Cancer Res."},{"key":"76862_CR70","doi-asserted-by":"publisher","first-page":"e1005895","DOI":"10.1371\/journal.pgen.1005895","volume":"12","author":"L Jiang","year":"2016","unstructured":"Jiang, L. et al. Genomic landscape survey identifies SRSF1 as a key oncodriver in small cell lung cancer. PLoS Genet 12, e1005895 (2016).","journal-title":"PLoS Genet"},{"key":"76862_CR71","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550\u20131558 (2018).","journal-title":"Nat. Med."},{"key":"76862_CR72","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76862-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76862-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76862-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:47:04Z","timestamp":1790308024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76862-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76862"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76862-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10050"}}